Transfusion-related costs in anemic myelofibrosis patients treated with JAK inhibitors in Germany
Abstract
Background: Myelofibrosis (MF) is a rare malignancy marked by splenomegaly, symptoms and anemia. Although Janus kinase inhibitors (JAKi) are central to MF therapy, many patients require additional anemia management, particularly red blood cell transfusions (RBC‑T). These impose substantial patient burden, yet their economic impact is sparsely investigated. This study estimates RBC‑T-related costs in anemic MF patients treated with JAKi in Germany from the payer perspective.
Methods: Nationwide, anonymized administrative claims data from 2014-2024 were retrospectively analysed. Eligible patients had an MF diagnosis (ICD‑10‑GM D47.1, D47.4, C94.6), received ruxolitinib or fedratinib, and ≥1 anemia treatment within 100 days before or during JAKi therapy. The index date was the first anemia therapy. Mean annual therapy costs (ATC) per patient included outpatient and inpatient costs for RBC-T and iron chelation therapy (ICT). Outpatient RBC-T units were identified via EBM codes and inpatient units via OPS codes. RBC-T unit counts were linked to estimated external unit, service and laboratory costs. ICT costs were directly obtained from claims. Subgroup analyses were conducted by JAKi therapy line and transfusion status.
Results: In total, 157 patients were included (mean age 72.7 years; 70.1% male). Overall RBC-T-related ATC (standard deviation) per patient were €5,936 (€2,402). ATC varied across subgroups: patients treated with ruxolitinib incurred €5,806 (€2,396), while those receiving fedratinib after prior ruxolitinib had €9,374 (€2,732). Transfusion‑dependent patients showed the highest ATC (€11,882 [€3,543]), followed by transfusion‑requiring (€3,904 [€1,196]) and transfusion‑independent patients (€910 [€371]).
Conclusions: The economic burden related to RBC-T in anemic MF patients treated with ruxolitinib or fedratinib is substantial. Results highlight the need for therapies that effectively address anemia in MF to help reduce associated resource utilization.
Key messages: • Transfusions impose a high economic burden in anemic myelofibrosis patients on JAK inhibitors, with greatest costs in second‑line fedratinib and transfusion‑dependent patients.
• The high transfusion burden underscores the need for therapies that better manage anemia and lessen reliance on transfusion-related resources.
Related
- 971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study
- Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors
- Systematic Review and Meta-Analysis on Central and/or Peripheral Nervous System Demyelination in Patients Treated With Tumor Necrosis Factor Alpha (TNF-α) Inhibitors
- Risk Factors for Pneumonitis in Patients with Unresectable Advanced Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
- Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors
BibTeX
@article{krammer2026transfusionrelated,
title = {{Transfusion-related costs in anemic myelofibrosis patients treated with JAK inhibitors in Germany}},
author = {M Krammer and C Iwamoto and FS Nikitas and F Karl and E Gleißner and X Yang and R Norris and A Farrer},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.1820},
url = {https://doi.org/10.1093/eurpub/ckag169.1820},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Transfusion-related costs in anemic myelofibrosis patients treated with JAK inhibitors in Germany
AU - M Krammer
AU - C Iwamoto
AU - FS Nikitas
AU - F Karl
AU - E Gleißner
AU - X Yang
AU - R Norris
AU - A Farrer
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.1820
UR - https://doi.org/10.1093/eurpub/ckag169.1820
AB - Background: Myelofibrosis (MF) is a rare malignancy marked by splenomegaly, symptoms and anemia. Although Janus kinase inhibitors (JAKi) are central to MF therapy, many patients require additional anemia management, particularly red blood cell transfusions (RBC‑T). These impose substantial patient burden, yet their economic impact is sparsely investigated. This study estimates RBC‑T-related costs in anemic MF patients treated with JAKi in Germany from the payer perspective. Methods: Nationwide, anonymized administrative claims data from 2014-2024 were retrospectively analysed. Eligible patients had an MF diagnosis (ICD‑10‑GM D47.1, D47.4, C94.6), received ruxolitinib or fedratinib, and ≥1 anemia treatment within 100 days before or during JAKi therapy. The index date was the first anemia therapy. Mean annual therapy costs (ATC) per patient included outpatient and inpatient costs for RBC-T and iron chelation therapy (ICT). Outpatient RBC-T units were identified via EBM codes and inpatient units via OPS codes. RBC-T unit counts were linked to estimated external unit, service and laboratory costs. ICT costs were directly obtained from claims. Subgroup analyses were conducted by JAKi therapy line and transfusion status. Results: In total, 157 patients were included (mean age 72.7 years; 70.1% male). Overall RBC-T-related ATC (standard deviation) per patient were €5,936 (€2,402). ATC varied across subgroups: patients treated with ruxolitinib incurred €5,806 (€2,396), while those receiving fedratinib after prior ruxolitinib had €9,374 (€2,732). Transfusion‑dependent patients showed the highest ATC (€11,882 [€3,543]), followed by transfusion‑requiring (€3,904 [€1,196]) and transfusion‑independent patients (€910 [€371]). Conclusions: The economic burden related to RBC-T in anemic MF patients treated with ruxolitinib or fedratinib is substantial. Results highlight the need for therapies that effectively address anemia in MF to help reduce associated resource utilization. Key messages: • Transfusions impose a high economic burden in anemic myelofibrosis patients on JAK inhibitors, with greatest costs in second‑line fedratinib and transfusion‑dependent patients. • The high transfusion burden underscores the need for therapies that better manage anemia and lessen reliance on transfusion-related resources.
SN - 1101-1262
SN - 1464-360X
ER -